Cholesterol crystal embolization-associated renal failure after therapy with recombinant tissue-type plasminogen activator.
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (t-PA). No invasive vascular procedure had been performed. Although there is one case report of cholesterol crystal embolization following t-PA therapy with only extrarenal manifestations (N Engl J Med 321:1270, 1989), this is the first reported case of atheroembolic acute renal failure following t-PA therapy.
Gupta
B K
BK
Department of Medicine, Booth Memorial Medical Center, Flushing, NY 11355.
Spinowitz
B S
BS
Charytan
C
C
Wahl
S J
SJ
D058186:Acute Kidney Injury / Q000209:etiology*; D000368:Aged; D002784:Cholesterol / Q000737:chemistry; D003460:Crystallization; D004617:Embolism / Q000139:chemically induced* / Q000150:complications; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000009:adverse effects; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects*
D011994:Recombinant Proteins; D002784:Cholesterol; D010959:Tissue Plasminogen Activator